MOUD Buprenorphine Sublocade denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sublocade as Not FDA-Approved — and Why That Denial Is Factually Incorrect

A "not FDA-approved" denial for Sublocade is almost certainly an administrative or coding error. Sublocade (extended-release injectable buprenorphine) received full FDA approval for the treatment of moderate-to-severe opioid use disorder in adults. It is not a compounded drug, it is not an unapproved investigational agent, and it is not being used off-label when prescribed for its FDA-labeled indication. This type of denial warrants an immediate appeal, because the factual premise of the denial is wrong.

## Common Causes of This Denial

• Incorrect drug code, NDC, or J-code submitted on the claim or prior authorization request.
• The plan's formulary system misclassified the product.
• The review was conducted against an outdated policy that predates approval.

Before filing a formal appeal, ask the prescriber's office or pharmacy to verify that the correct NDC or billing code was submitted. Correcting a coding error can resolve the denial without a formal appeal.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal with proof of FDA approval attached. The timeframe to appeal is shown on your denial letter — do not miss it.
• External review: After internal exhaustion, you have the right to independent external review under ACA §2719. The window is generally up to four months from the internal denial notice. An external reviewer who sees the FDA approval documentation will find the denial without clinical support.
• Expedited appeal: If the patient faces urgent health risk without the medication, request expedited review with prescriber documentation of urgency.

## Concrete Appeal Steps

1. Obtain the full denial letter and identify the exact language used. 2. Download the FDA prescribing label for Sublocade directly from Drugs@FDA — this is the primary evidence document. 3. Verify with the prescribing office that the correct drug code was submitted. 4. Write a brief appeal letter that (a) attaches the FDA label, (b) states the labeled indication, and (c) requests the plan identify the specific policy provision under which a fully FDA-approved drug for its labeled indication is excluded. 5. If the plan cannot cite a valid coverage exclusion, it must cover the drug.

## Documentation to Gather

• FDA prescribing label: Printed from Drugs@FDA, showing the product name, approval date, and labeled indication.
• Diagnosis confirmation: DSM-5 diagnosis of moderate-to-severe OUD, matching the FDA-labeled indication.
• Claim/PA submission record: Copy of the original prior authorization or claim submission, to verify correct coding.
• Prescriber letter: Confirming the drug, indication, and that this is an FDA-approved use.
• Criteria-mapping table: If UHC's coverage policy has any additional requirements beyond FDA approval, map each one to the corresponding chart documentation.

## Criteria-Mapping Structure

For this denial type, the mapping table is short: FDA-approved for [indication] → attach label. Diagnosis matches labeled indication → attach chart note. If the plan adds further criteria (e.g., prior authorization steps), list and answer each. Keep the appeal letter factual, brief, and evidence-anchored — the strength of this appeal is documentary, not narrative.